Alto Neuroscience Inc (ANRO): Price to Sales

Brandmark of Alto Neuro (ANRO)

Alto Neuroscience, Inc. (ANRO) integrates the principles of bioethics and cybersecurity with the development of precision neuropsychiatric drugs. The price-to-sales ratio trend reflects current market dynamics, where becomes the new value for this metric. The business is currently spending its existing capital on costly trials without generating operating income, aiming to monetize personalized therapy in the future through insurance reimbursements and medical centers.

Price-to-Revenue Ratio: altoneuroscience.com (ANRO) for 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for Alto Neuro (ANRO)

- share price and consensus valuation forecast:
Price Performance Chart altoneuroscience.com|ANRO - Price Target Chart
- stock exchange capitalization data:
Market Value Alto Neuro|ANRO - Enterprise Value
- shareholders' equity book value data:
Book Value per Share Alto Neuroscience|ANRO - Company Book Value|Market Value to Book Value Ratio altoneuroscience.com|ANRO - Cumulative Company Assets
- debt obligations and liquidity statistics:
Aggregate Debt to Capital Alto Neuroscience, Inc.|ANRO - Long-Term Debt to Equity|Current Liabilities to Capital Alto Neuroscience Corp|ANRO - Company Total Debt|Debt to Net Assets Ratio Alto Neuro|ANRO - Company Long-Term Debt|Company Short-Term Indebtedness Alto Neuroscience|Immediate Liquidity altoneuroscience.com
- company profitability and valuation multiples indicators:
ANRO - Net Income|Projected Future Earnings Alto Neuroscience, Inc.|ANRO - Price to Earnings Ratio|Future Price to Earnings Multiple Alto Neuroscience Inc|ANRO - Price/Earnings to Growth Ratio|Company Value to EBITDA Alto Neuro|ANRO - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Alto Neuroscience|ANRO - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months altoneuroscience.com|ANRO - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Alto Neuroscience, Inc.
- total revenue and sales volume data:
ANRO - Revenue and Sales Volume|Company Expected Sales Volume altoneuroscience.com|ANRO - Price-to-Revenue Ratio|Market Cap to Projected Revenue Alto Neuro
Summary company analytics:altoneuroscience.com, ANRO
Brand item of Alto Neuroscience

Long-term investing requires strict control over asset revaluation relative to actual earnings. For Alto Neuroscience, Inc. (ANRO), this risk is amplified by the dependence of market capitalization on the outcomes of clinical trials for biomarker drugs. This price-to-sales ratio measures the premium the market is willing to pay for future sales growth. An increase in this metric signals inflated expectations, creating the threat of a sharp correction in the share price.

Competitors of Alto Neuroscience, Inc.

ALKS (alkermes.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Avadel Pharmaceuticals plc AVDL|atai Life Sciences NV (ATAI) - Price to Sales|GH Research Corp - P/S Multiple|MNMD - P/S Multiple|COMPASS Pathways plc (CMPS) - Price-to-Revenue Ratio|LBRX (lbpharma.us) - Price-to-Revenue Ratio|Market Cap to Revenue DRUG|VNDA (Vanda Pharma) - Market Cap to Sales Volume|Price-to-Revenue Ratio Cybin Inc. (CYBN)|NRXP - Price to Sales|Cingulate - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio SILO|CPHI - Price-to-Revenue Ratio|CMND (clearmindmedicine.com) - Market Cap to Revenue Ratio|PBM: P/S Multiple|Price to Sales SciSparc Corp (SPRC)|Market Cap to Revenue SEEL|P/S Multiple Virpax|Price-to-Revenue Ratio Karuna Therapeutics, Inc. (KRTX)